Arkolith/Insider Trading/SPRO/Form 4

Keutzer Timothy

Chief Development OfficerSpero Therapeutics, Inc. (SPRO) · full profile →Form 4 · filed Aug 30, 2023
Net Selling
Open-Market Buys
$0
Open-Market Sells
$2K
Net Open-Market Flow
-$2K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 28, 2023Sell(S)2K$1.26$2K325K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-23-045450) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML